<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116410</url>
  </required_header>
  <id_info>
    <org_study_id>HS-20094-101</org_study_id>
    <nct_id>NCT05116410</nct_id>
  </id_info>
  <brief_title>A Study of HS-20094 in Healthy Participants</brief_title>
  <official_title>A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-20094</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study includes two parts (Single Ascending Dose, SAD; Multiple-Ascending Dose, MAD) and&#xD;
      enrolls healthy participants. Participants in SAD accept single subcutaneous (SC) injection&#xD;
      of HS-20094 and participants in MAD accept SC injection of HS-20094 once weekly for 4 weeks.&#xD;
      The main purpose of this study is to determine 1) The safety of HS-20094; 2) How much&#xD;
      HS-20094 gets into the bloodstream and how long it takes the body to get rid of it.3) How&#xD;
      HS-20094 affects the levels of blood sugar, insulin and weight.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse event (AE), serious adverse event (SAE), AE leading to study discontinuation, AE severity and relation with study drug</measure>
    <time_frame>Time of Inform Consent Form to Day 29 (SAD) or Day 50 (MAD)</time_frame>
    <description>A summary of AEs and SAEs, AE leading to study discontinuation, AE severity and relation with study drug will be reported in the reported adverse events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Cmax of HS-20094</measure>
    <time_frame>Baseline to Day 22 (SAD) or Day 43 (MAD)</time_frame>
    <description>PK: Cmax of HS-20094</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of HS-20094</measure>
    <time_frame>Baseline to Day 22 (SAD) or Day 43 (MAD)</time_frame>
    <description>PK: AUC of HS-20094</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Tmax of HS-20094</measure>
    <time_frame>Baseline to Day 22 (SAD) or Day 43 (MAD)</time_frame>
    <description>PK: Tmax of HS-20094</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): AUC of glucose</measure>
    <time_frame>Day 22 (MAD)</time_frame>
    <description>PD: AUC of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): AUC of insulin</measure>
    <time_frame>Day 22 (MAD)</time_frame>
    <description>PD: AUC of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>baseline to Day 29 (SAD) or Day 50 (MAD)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>HS-20094 (Single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of HS-20094 administered subcutaneously (SC) once in healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HS-20094 (Multiple doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of HS-20094 administered SC once weekly for four weeks in healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Single dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC once in healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Multiple doses)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC once weekly for four weeks in healthy participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-20094</intervention_name>
    <description>Administrated SC</description>
    <arm_group_label>HS-20094 (Multiple doses)</arm_group_label>
    <arm_group_label>HS-20094 (Single dose)</arm_group_label>
    <other_name>HS-20094 injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administrated SC</description>
    <arm_group_label>Placebo (Multiple doses)</arm_group_label>
    <arm_group_label>Placebo (Single dose)</arm_group_label>
    <other_name>Placebo injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Screening weight of male ≥50 kg, female≥45 kg and 19≤BMI≤28&#xD;
&#xD;
          2. Subjects agree to use an effective method of contraception and avoid sperm or egg&#xD;
             donation for the duration of the study and for 6 months following the last dose of&#xD;
             investigational product&#xD;
&#xD;
          3. Agree to avoid alcohol, foods and beverages containing xanthine or caffeine (including&#xD;
             chocolate, tea, coffee, cola, etc.) from 48 hours prior to administration to last&#xD;
             visit, and to avoid strenuous exercise&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women&#xD;
&#xD;
          2. Subjects have a medical history of cardiovascular, respiratory, liver, kidney,&#xD;
             digestive tract, mental, neurological, hematology or metabolic abnormalities (e.g.,&#xD;
             repeated hypoglycemia for unknown reasons) and are judged not suitable for this study&#xD;
             by the investigator.&#xD;
&#xD;
          3. Subjects with abnormal screening vital signs, physical examination, laboratory&#xD;
             examination or 12 lead electrocardiogram results with clinical significance&#xD;
&#xD;
          4. Have a history of drug allergy, or known allergies to HS-20094, glucagon-like peptide&#xD;
             (GLP)-1 analogs, or glucose-dependent insulinotropic polypeptide (GIP) receptor&#xD;
             agonism&#xD;
&#xD;
          5. Received systemic steroid therapy, immunomodulator therapy or chemotherapy in the 3&#xD;
             months prior to screening, or are likely to receive these treatments during the study&#xD;
             period&#xD;
&#xD;
          6. Have a history of digestive disease (e.g., gastroesophageal reflux disease,&#xD;
             gallbladder disease, or chronic enteritis) that may affect gastrointestinal adverse&#xD;
             events assessment or any other gastrointestinal disease (e.g., gastric bypass surgery,&#xD;
             pyloric stenosis, etc.) that may affect gastric emptying&#xD;
&#xD;
          7. Have a diet, weight loss treatment or significant lifestyle changes prior to 30 days&#xD;
             of administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yimin Cui</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yimin Cui, PhD</last_name>
    <phone>66110802</phone>
    <phone_ext>010</phone_ext>
    <email>cuiymzy@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

